Stock listing

F6T Stock Price, News, Filings & Events — Fate Therapeutics, Inc.

Selected listing: F6T · GETTEX · EUR · DE

This page tracks Fate Therapeutics, Inc.'s F6T:GETTEX listing on GETTEX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following F6T:GETTEX. F6T:GETTEX is the stock-level entry point for investors researching Fate Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Fate Therapeutics, Inc. is a public biotechnology company based in the United States, focused on developing cellular immunotherapies for cancer and immune disorders. The company is traded under the ticker symbol FATE and has a market capitalization of approximately $280.9 million. Fate Therapeutics aims to advance its innovative therapies through research and development in the field of regenerative medicine.

F6T:GETTEXEURDEUpdated September 11, 2026
Fate Therapeutics, Inc. logo
Ticker
F6T:GETTEX
Asset type
Stock
Market cap
$276.8M
Sector
Health Technology
Industry
Biotechnology
Exchange
GETTEX
Currency
EUR

Fate Therapeutics, Inc. F6T:GETTEX stock context

This page tracks Fate Therapeutics, Inc.'s F6T:GETTEX listing on GETTEX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following F6T:GETTEX. F6T:GETTEX is the stock-level entry point for investors researching Fate Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Fate Therapeutics, Inc. is a public biotechnology company based in the United States, focused on developing cellular immunotherapies for cancer and immune disorders. The company is traded under the ticker symbol FATE and has a market capitalization of approximately $280.9 million. Fate Therapeutics aims to advance its innovative therapies through research and development in the field of regenerative medicine.

Latest news from Fate Therapeutics, Inc.

All Fate Therapeutics, Inc. news →

Fate Therapeutics, Inc. earnings calls

Research Fate Therapeutics, Inc.

Alternate listings